

Timothy L Vollmer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8498205/publications.pdf>

Version: 2024-02-01

19
papers

3,161
citations

933447

10
h-index

996975

15
g-index

19
all docs

19
docs citations

19
times ranked

3397
citing authors

#	ARTICLE	IF	CITATIONS
1	B-Cell Depletion with Rituximab in Relapsing/Remitting Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2008, 358, 676-688.	27.0	2,107
2	Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. <i>Annals of Neurology</i> , 2009, 66, 460-471.	5.3	815
3	International consensus on quality standards for brain health-focused care in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1809-1818.	3.0	55
4	Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptides. <i>PLoS ONE</i> , 2020, 15, e0228883.	2.5	33
5	Multiple Sclerosis Phenotypes as a Continuum. <i>Neurology: Clinical Practice</i> , 2021, 11, 342-351.	1.6	30
6	Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. <i>Neurology: Clinical Practice</i> , 2018, 8, 292-301.	1.6	25
7	Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. <i>Neurology</i> , 2019, 92, e723-e732.	1.1	24
8	Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1466-1476.	3.7	22
9	Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. <i>Journal of the Neurological Sciences</i> , 2019, 407, 116498.	0.6	14
10	Glatiramer acetate ameliorates experimental autoimmune neuritis. <i>Immunology and Cell Biology</i> , 2014, 92, 164-169.	2.3	12
11	Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 55, 103170.	2.0	8
12	Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732110693.	1.0	5
13	Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate. <i>Frontiers in Neurology</i> , 2020, 11, 1045.	2.4	4
14	A Longitudinal, Observational Analysis of Neuronal Injury Biomarkers in a Case Report of a Patient With Paraneoplastic Anti-CRMP5 Antibody-Associated Transverse Myelitis. <i>Frontiers in Neurology</i> , 2021, 12, 691509.	2.4	4
15	Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110195.	3.5	3
16	Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptides. , 2020, 15, e0228883.		0
17	Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptides. , 2020, 15, e0228883.		0
18	Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptides. , 2020, 15, e0228883.		0

#	ARTICLE	IF	CITATIONS
19	Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptides. , 2020, 15, e0228883.		0